Oligometastatic disease and oligoprogression in gastrointestinal cancers.

Abstract

Oligometastatic disease has fundamentally altered how we approach metastatic gastrointestinal (GI) cancers, blurring the boundary between curable and incurable disease. Patients with limited metastatic burden may benefit from metastasis-directed therapy (MDT) aimed at long-term disease control or even cure. In selected settings, randomized studies have demonstrated meaningful improvements in progression-free survival, and contemporary series report 5-year overall survival rates of approximately 30-65% in carefully selected patients undergoing MDT. The concept of oligoprogression-isolated sites of progression despite otherwise stable disease-has become particularly relevant as modern systemic therapies have extended disease control in many patients. Emerging data suggest that timely local consolidation at oligoprogressive sites may allow patients to continue effective systemic regimens and delay treatment switches. Successful application of MDT with either palliative or curative intent depends on careful multidisciplinary assessment. Disease kinetics, molecular and/or genomic features, response to prior treatment, and individual patient characteristics all factor into decision-making. Critically, the strength of evidence varies considerably across GI tumor types, and not all oligometastatic disease is created equal. Radiotherapy also serves an essential palliative function, addressing common symptoms including bleeding, obstruction, and pain. This review examines the current evidence and explores unresolved questions about when and how to deploy local therapy across the spectrum of metastatic GI primary tumors.